X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cardiovascular market: A snapshot - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Aug 4, 2001

    Cardiovascular market: A snapshot

    How often have you heard a person complaining about diabetes? Quite often, right? With increasing level of urbanization, stress index levels have moved in tandem. Diabetes, heart diseases and other life style problems are on the rise. No wonder cardiovascular market is the largest and fastest growing therapeutic segment in the global pharmaceutical market. The global cardiovascular market is estimated to be US$ 46 bn, which is around 10% of the world pharma market and is clocking double-digit growth rates.

    A patient once afflicted with cardiac problem usually carries the problem through his lifetime and brand switching is lowest in this segment. Cardiovascular segments thus attract larger pie of R&D budget of pharma companies worldwide and new drugs are continually rolled out on a regular basis.

    India has the fastest growing diabetes patients, thanks to rapid expansion of urbanization. Statistics rolled out by World Health Organisation predicts in about two decades the number of diabetes patients would leap frog to about 57 m from the current 27 m patients.

    The domestic market for cardiovascular segment is estimated to be Rs 9.3 bn, which means a market share of around 7%. The cardiovascular market in India has grown at compounded average rate of 28% in last one decade and has outsmarted all other therapeutic markets.

    Cardiovascular Market: Segment wise break-up
    Sub-Segment Market Size
    (Rs m)
    Growth
    Rate (%)
    Beta Blockers 1,318 23.5
    ACE Inhibitors 1,259 13.9
    Calcium Channel Blockers 2,026 14.4
    Hypotensives 945 32.9
    Diuretics 335 36.6
    Others 823 14.6

    Anti-anginals and Hypotensives are broad sub-segments within the cardiovascular category. Anti-anginals are drugs used to remove blockage in arteries ultimately controlling chest pain. Anti-hypertensives are used to control high blood pressures. Diuretics are used to reduce excess level of sodium salt in the body. Usually, patients are required to use multiple drug/medicines for cardiac therapy and thus pharma companies use various combinations of molecules.

    The leading players in cardiovascular therapy are mostly domestic companies like Sun Pharma, Torrent, Cadila and ICI Pharma. Share of MNCs is relatively low and their portfolio consists of relatively older molecules.

    Apart from the fact that the segment is provides fast growth rates, the margins in the segment are higher due to very limited DPCO exposure. All this is attracting companies to concentrate on this therapeutic segment. Moreover, considering the lifestyle nature of problems, affordability issue is not a major concern in this segment.

    Exports of cardiovascular formulations till date have been relatively marginal in the cardiovascular segment. The silver lining is that generic export market for cardiovascular products might open up for Indian companies in a big way in coming years, as some of the prominent molecules in the segment go off patent. However, to sustain export growth in the long-term companies will have race up their research capabilities.

    Considering the lucrative market, the segment has higher chances of MNC’s aggressively launching blockbuster products in India post 2005 (when patent protection would be a reality). So brand positioning and basic research will be the key to success and survival for domestic companies. Domestic companies will have to undertake basic research by choice and compulsion to compete against their international counterparts. Otherwise they better have their ‘pulse’ checked at an earlier date.

     

     

    Equitymaster requests your view! Post a comment on "Cardiovascular market: A snapshot ". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 18, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS